# Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

> **NCT07081607** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Peripheral T-Cell Lymphoma, Not Classified

## Interventions

- **DRUG:** golidocitinib with azacytidine and chidamide

## Key facts

- **NCT ID:** NCT07081607
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-15
- **Primary completion:** 2026-07-16
- **Final completion:** 2028-07-16
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07081607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07081607, "Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07081607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*